Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
PHASE3RecruitingINTERVENTIONAL
Enrollment
100
Participants
Timeline
Start Date
June 30, 2008
Primary Completion Date
December 31, 2020
Study Completion Date
December 31, 2025
Conditions
Nephrotic Syndrome
Interventions
DRUG
Rituximab
Trial Locations (1)
Unknown
RECRUITING
National University Hospital, Singapore
All Listed Sponsors
lead
National University Health System, Singapore
OTHER
NCT03501459 - Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome | Biotech Hunter | Biotech Hunter